CLINICAL
Research
Our non-endoscopic technologies give doctors access to less invasive and better diagnostics for esophageal diseases.
In recent years, this field has witnessed groundbreaking developments. We are harnessing the full potential of cutting-edge and AI-driven tools to transform the landscape of gastroenterological healthcare.
In recent years, this field has witnessed groundbreaking developments. We are harnessing the full potential of cutting-edge and AI-driven tools to transform the landscape of gastroenterological healthcare.
Current Studies
DETECT-ME
Validation study for novel molecular biomarkers to diagnose Barrett's esophagus and esophageal neoplasia using EndoSign cell collection device.
Study status:
Active
Patient numbers:
700
Use case:
Barrett's esophagus and esophageal neoplasia
BEST4
Screening for Barrett’s esophagus, proactively inviting and testing at-risk patients with EndoSign®-TFF3 to reduce deaths of esophageal cancer.
Study status:
Active
Patient numbers:
140,000
Use case:
Barrett's eophagus
Get involved
QuBIE
Treatment response prediction for Eosinophilic esophagitis, validation of novel biomarkers to predict response to select therapies
Study status:
Active
Patient numbers:
250
Use case:
Eosinophilic Esophagitis
.jpg)
ADVANCED TECHNOLOGY
Capsule sponge advancements are empowering physicians to make more informed and precise decisions in their daily practice, leading to enhanced patient care and better outcomes.
We are dedicated to teaming up with businesses, organizations, and institutions to integrate EndoSign® into the frontline defense against esophageal cancer and other diseases.
Academic & Research
If you want to understand more about how capsule sponge testing can be used in your research study or workflow:
Get in touch
Pharma & Life Sciences
Find out how our technology and machine learning capabilities can help you with your research, clinical trials and commercialization:
Get in touch